Prenetics Global Limited (PRE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant revenue and gross profit growth, improved EBITDA, and strong liquidity. The introduction of a 90-day offering and AI utilization further enhances operational efficiency. Positive market sentiment is reinforced by optimistic guidance and strategic expansion plans, including new SKUs and localization efforts. Although some details were withheld, the overall financial performance and strategic initiatives suggest a positive stock price movement.
Key Financial Performance
Revenue (Q4 2025) $36.6 million, a 457% increase year-over-year, driven by IM8 contributing $27.4 million in Q4.
Revenue (Full Year 2025) $92.4 million, a 480% increase year-over-year, driven by the launch of IM8 and strategic focus on high-margin opportunities.
Gross Profit (Q4 2025) $21.7 million, an 804% increase year-over-year, with a consolidated gross margin of 59%, reflecting improved operational efficiency.
Gross Profit (Full Year 2025) $48.9 million, a 428% increase year-over-year, driven by IM8's contribution and divestiture of low-margin businesses.
Adjusted EBITDA Loss (Q4 2025) $2.3 million, a 70.4% improvement year-over-year, demonstrating significant operating leverage.
Adjusted EBITDA Loss (Full Year 2025) $13 million, a 27% improvement year-over-year, reflecting better cost management and operational efficiency.
IM8 Revenue (Full Year 2025) $60.1 million, with a healthy 63% gross margin, highlighting its role as a key growth driver.
Balance Sheet Liquidity (as of February 15, 2026) $171.1 million in total adjusted liquid assets, including cash, financial assets, and BTC holdings, with 0 debt, providing financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IM8 launch: IM8, a premium consumer health brand co-founded with David Beckham, achieved a $120 million annualized revenue run rate in its first year, marking one of the fastest growth trajectories in the global supplement industry.
New product announcements: Two new products are planned for launch in Q4 2026, targeting large total addressable markets to diversify the portfolio and accelerate growth.
Global expansion of IM8: IM8 achieved global reach with 40% of revenues from the U.S. and 60% internationally across 30 markets. The company plans to invest further in IM8's global expansion.
Revenue growth: Record revenue of $92.4 million in 2025, a 480% year-over-year increase, driven by IM8.
Profitability roadmap: Clear roadmap to adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and operating leverage.
Divestiture of noncore assets: Sold ACT Genomics for $72 million, exited Europa business in a $30 million all-stock deal, and sold a 35% stake in Insighta to Tencent for $70 million in cash, strengthening the balance sheet.
Financial position: Total liquidity of $171 million with zero debt as of February 2026.
Strategic pivot: Shifted focus to becoming a pure-play consumer health leader by divesting noncore assets, improving margin profile, and sharpening focus on high-growth opportunities.
Subscription model shift: Prioritized quarterly subscriptions in early 2026, doubling average order value from $110 to $233 and achieving an 80% new customer subscription rate.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company has not explicitly mentioned any regulatory challenges, but the divestiture of non-core assets and the strategic pivot to consumer health may involve compliance with new regulatory frameworks in different markets.
Market Competition: The company faces competitive pressures in the global supplement industry, especially as it aims to scale IM8 into a $1 billion global brand. The presence of established players and new entrants could impact market share and profitability.
Economic Uncertainty: Economic conditions in international markets could affect consumer spending on premium health products, potentially impacting revenue growth for IM8.
Strategic Execution Risks: The company’s ambitious growth targets, including achieving adjusted EBITDA profitability by Q4 2027 and scaling IM8 globally, depend on flawless execution of its strategy. Any missteps could delay or derail these objectives.
Supply Chain Risks: Although not explicitly mentioned, scaling IM8 globally across 30 markets could expose the company to supply chain disruptions, which may affect product availability and customer satisfaction.
Financial Risks: The company plans to invest heavily in marketing to drive growth, leading to an adjusted EBITDA loss of $16 million to $20 million in 2026. This could strain financial resources if revenue growth does not meet expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
IM8 Revenue Projections for 2026: Prenetics expects IM8 revenue to reach approximately $180 million to $200 million for the full year 2026, representing nearly 300% year-over-year growth.
Gross Margin Target for 2026: The company is targeting a gross margin of approximately 60% for the full year 2026.
Adjusted EBITDA Loss for 2026: Prenetics anticipates a full-year adjusted EBITDA loss of approximately $16 million to $20 million in 2026, with a clear path to achieving adjusted EBITDA profitability by Q4 2027.
New Product Launches in Q4 2026: The company plans to announce two new products in Q4 2026, targeting large total addressable markets to diversify its portfolio and accelerate growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the reasoning behind the 90-day offering and its expected benefits?
A:The 90-day offering was introduced after testing in the U.S. showed consumer preference for this option. It provides benefits such as saving consumers $10 monthly, increasing average order value from $130 to $233, and shortening the payback period for customer acquisition costs. Additionally, it improves logistics efficiency and is expected to increase retention rates due to the product's effectiveness over 90 days.
Q:Can you provide more information about the timing and nature of the two new SKUs planned for release this year?
A:The two new SKUs are planned for release by the end of Q4 this year. While details are withheld for competitive reasons, they will be in the health and performance space, specifically in the health supplement category, targeting large markets with competitors generating $500 million to $1 billion annually.
Q:What trends have been observed so far this year, and are the new products included in the revenue guidance of $180 million to $200 million?
A:The company has observed continued momentum on a month-over-month basis. The revenue guidance of $180 million to $200 million does not include the new products.
Q:What are the customer acquisition costs (CAC) and lifetime values for IM8, and how have they trended over time?
A:The CAC is approximately $130, with a payback period of 3.4 months. The average order value has increased from $110 to $233, and CAC has increased proportionally. Marketing efforts are primarily on Meta (85%) and Google (15%), with plans to diversify into YouTube, podcasts, AppLovin, and TikTok.
Q:How is the company leveraging artificial intelligence (AI) in its operations?
A:The company uses AI across all functions, including digital marketing. For example, it rolls out 800-1,000 new ads weekly, identifies winning ads, and replicates them. An AI-generated video featuring Aryna Sabalenka reached 233 million views, significantly aiding customer targeting. AI is also used in international localization efforts.
Q:What is the company's strategic M&A strategy, and how do they decide between building and buying?
A:The company focuses on organic growth due to its strong performance marketing flywheel. However, it remains open to strategic M&A opportunities if they align with its goals.
Q:How much of the revenue growth this year is expected from customer base expansion versus average revenue per user uplift from quarterly plans?
A:The majority of revenue growth is expected from new customers. The U.S. market, which represented $23 million of $60 million last year, has significant growth potential, with the ability to support $300 million to $400 million in revenue for the product.
Q:What revenue uplift has been observed from localizing websites, and which international markets are most promising?
A:Localization efforts are expected to increase revenue by 10%-15% in local markets. Germany, currently ranked #8 or #9 globally, is a key focus for localization by Q2 this year.
Q:What are the key factors to achieving the Q4 2027 EBITDA profitability target, and is there an accompanying EPS target?
A:Key factors include scaling revenue to $250 million-$300 million, leveraging gross margins (currently at 60%, with potential to increase to 62%-63%), and achieving cost efficiencies. No specific EPS target was mentioned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the two new SKUs planned for release, citing competitive reasons. Additionally, no specific EPS target was provided for the Q4 2027 EBITDA profitability goal.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTC
Chief Executive
Dr
Europa
Executive Officer
Full
Mr
Prenetics
Securities
asset
balance sheet
bank
brand
capital
cash
consumer health
coverage
credibility
customer
date
debt
discussion factor
focus
future
increase
information
launch
leverage
line
longevity
loss
margin
market
month
rate
result
statement
story
today
trajectory
value
PRE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
